title: Pharmacogenetic tests: the need for a level playing field.
abstract: The delivery of more personalized medicinecould be accelerated by addressing the substantial differences in the level of evidence required for the inclusion of pharmacogenetic tests in treatment guidelines, drug labelling and reimbursement schemes compared with that needed for non-genetic diagnostic tests.
authors.affiliation: Department of Molecular and Clinical Pharmacology, Wolfson Centre for Personalised Medicine, University of Liverpool, Liverpool, UK. munirp@llv.ac.uk
authors.forename: Munir
authors.initials: M
authors.lastname: Pirmohamed
authors.forename: Dyfrig A
authors.initials: DA
authors.lastname: Hughes
mesh_terms: D015195:Drug Design; D004348:Drug Labeling; D005820:Genetic Testing / Q000379:methods*; D006801:Humans; D010597:Pharmacogenetics; D017410:Practice Guidelines as Topic; D057285:Precision Medicine / Q000379:methods*; D012051:Reimbursement Mechanisms